Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.


Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.


  • Product Code: X1355M
  • Size: 100 µg
  • Price (USD): $433

Cat #

X1355M		 Quantity:      

Data Sheet

Product Name



Excision Repair Cross Complementing protein-1; Nucleotide Excision Repair Protein







Product Type

Monoclonal Antibody




Western Blot, Immunoprecipitation, Immunohistochemistry (Paraffin Sections)


Protein A/G Chromatography


100 µg

Price (USD)



Recognizes a protein of 33-36kDa, identified as the Excision Repair Cross Complementing (ERCC1). The mammalian ERCC1-encoded polypeptide is required for nucleotide excision repair (NER) of damaged DNA and is homologous to Saccharomyces cerevisiae RAD10, which functions in repair and mitotic intrachromosomal recombination. The structure-specific ERCC1/XPF endonuclease complex is implicated in the repair of two distinct types of lesions in DNA: NER for UV-induced lesions and bulky chemical adducts; and recombination repair of the very genotoxic interstrand cross-links. NER mechanism involves dual incisions on both sides of the damage catalyzed by two nucleases. In mammalian cells XPG cleaves 3' of the DNA lesion while the ERCC1-XPF complex makes the 5' incision. Elevated levels of ERCC1 have also been reported in Cisplatin-resistant cells.


Hybridoma produced by the fusion of spelocytes from BALB/c mice immunized with recombinant full length human ERCC1 protein and mouse myeloma Sp2/0 cells.

Positive Control

A431 or HeLa cells


Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Image

Image Legend

Immunohistochemical staining using ERCC1 antibody on formalin fixed, paraffin embedded human tonsil tissues.

Database Links:



1. Hayashi T, et al: ERCC1 mutations in UV-sensitive Chinese hamster ovary (CHO) cell lines. Mutat Res 1998;407(3):269-276.

2. de Laat WL, et al: DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem 1998;273(14):7835-7842.

3. de Laat WL, et al: Mapping of interaction domains between human repair proteins ERCC1 and XPF. Nucleic Acids Res 1998 Sep 15;26(18):4146-4152.

4. Lee-Kwon W, et al: Involvement of the Ras/extracellular signal-regulated kinase signalling pathway in the regulation of ERCC-1 mRNA levels by insulin. Biochem J 1998 Apr 15;331 ( Pt 2):591-597.

5. Lee-Kwon W, et al: Nucleotide excision repair is not required for the antiapoptotic function of insulin-like growth factor 1. Exp Cell Res 1998;241(2):458-466.

6. Li Q, Bostick-Bruton F, Reed E: Effect of interleukin-1 alpha and tumour necrosis factor- alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. Anticancer Res 1998;18(4A):2283-2287.

7. Li Q, Ding L, Yu JJ, Mu C, Tsang B, Bostick- Bruton F, Reed E: Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Int J Oncol 1998;13(5):987-992.

8. Lin YW, Kubota M, Koishi S, Sawada M, Usami I, Watanabe K, Akiyama Y: Analysis of mutations at the DNA repair genes in acute childhood leukaemia. Br J Haematol 1998;13(4):357-365.

9. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24(5):331-344.

10. Rolig RL, Lowery MP, Adair GM, Nairn RS: Characterization and analysis of Chinese hamster ovary cell ERCC1 mutant alleles. Mutagenesis 1998;13(4):357-365.

11. Li Q, Tsang B, Bostick-Bruton F, Reed E: Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol 1999;57(4):347-353.

12. Miura M, et al. Exp Cell Res 1996;226:126-132.